SecBot SecBot
EFFECT ·Filed Apr 28, 2026

RNXT

RenovoRx, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC9999999995-26-001342
IPO/offering going effective
Actionable Insight • Neutral

The effective shelf creates a standing dilution risk. Monitor for prospectus supplements indicating a takedown — any announced offering would likely pressure the stock given the small market cap. The prior S-3 for selling stockholder resale adds further overhang.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
RNXT ▲ +1.73% at T+60d
NEUTRAL call +1.73% · α vs SPY -2.26% · entry $0.8400 → $0.8545
Entry = T+0 close
Apr 28, 2026
via day close
T+1d
-1.07%
call -1.07% · α -1.06%
$0.8310
settled 6mo ago
T+5d
+10.48%
call +10.48% · α +8.78%
$0.9280
settled 6mo ago
T+20d
+10.83%
call +10.83% · α +5.38%
$0.9310
settled 5mo ago
T+60d
+1.73%
call +1.73% · α -2.26%
$0.8545
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

RenovoRx's S-3 shelf registration (File No. 333-295108) became effective on April 27, 2026. This allows the company to offer and sell up to $50 million in various securities from time to time, creating potential dilution overhang for the $39M market cap stock.

Key Facts

  • S-3 shelf registration became effective on April 27, 2026
  • Allows offerings of common stock, preferred stock, warrants, debt securities, and other securities
  • Total gross proceeds capped at $50,000,000
  • Company market cap is approximately $39M, making the shelf size significant relative to current valuation
  • A prior S-3 filed April 16, 2026 (12 days ago) covers resale of up to 15.96 million shares by selling stockholders

Financial Impact

Up to $50 million in potential gross proceeds from future offerings, though no specific offering is announced

dilution

Risk Factors

  • Potential dilutive offering at any time without further notice
  • Shelf size ($50M) exceeds current market cap ($39M), signaling significant potential dilution
  • Prior S-3 for resale of 15.96M shares by selling stockholders adds additional overhang

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001342
Document: 9999999995-26-001342-index.html9999999995-26-001342
Document: 9999999995-26-001342.txt9999999995-26-001342
17 reports for RNXT
Performance horizon
50% Hit rate @ T+60 2 of 4 directional calls Went positive at some point 2 of 4 best @ T+60▲ +43.56%May 26, 2026
Filters
Rows
Reports for RNXT — sortable, filterable
TypeNow
Oct 22, 2026
5d ago
Press Release
NEUTRAL ★ 1/10
$1.27awaiting T+60—$1.36 (+7.09%)
Jul 29, 2026
12w ago
Press Release
NEUTRAL ★ 1/10
$0.8981 $1.27▲ +41.41%▲ +36.68%$1.36 (+51.43%)
Jul 2, 2026
16w ago
8-K
BEARISH ★ 6/10
$0.9201 $1.68▼ −82.59%▼ −79.58%$1.36 (−47.81%)
May 26, 2026
22w ago
Press Release
BULLISH ★ 5/10
$0.9160 $1.32▲ +43.56%▲ +40.83%$1.36 (+48.47%)
May 19, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$0.8060 $1.26▲ +56.33%▲ +50.04%$1.36 (+68.73%)
May 15, 2026
23w ago
10-K/A
NEUTRAL ★ 4/10
$0.7830 $1.12▲ +43.04%▲ +38.19%$1.36 (+73.69%)
May 14, 2026
23w ago
8-K
BULLISH ★ 5/10
$0.8200 $1.15▲ +40.24%▲ +35.73%$1.36 (+65.85%)
Apr 29, 2026
25w ago
Press Release
NEUTRAL ★ 1/10
$0.8310 $0.8653▲ +4.13%▲ +0.02%$1.36 (+63.66%)
Apr 28, 2026
26w ago
EFFECT
NEUTRAL ★ 4/10
$0.8400 $0.8545▲ +1.73%▼ −2.26%$1.36 (+61.90%)
Apr 16, 2026
27w ago
S-3
NEUTRAL ★ 4/10
$1.00 $0.8500▼ −15.00%▼ −21.14%$1.36 (+36.00%)
Showing 10 of 17

US Market Status

Market Open — Closes in 3h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026